• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Galderma, Sofregen Enter Agreement to Develop Silk-based Biostimulators


Galderma and Sofregen Medical announced they have entered into an agreement to co-develop a novel line of silk-based biostimulators that will enable immediate volume restoration and provide structure for new tissue generation.

Galderma and Sofregen Medical, a medical device company focused on using silk protein for tissue building and regeneration, have announced they have signed a co-development and option-to-acquire agreement, according to a press release announcing the agreement.1

This agreement will build upon Galderma’s history of biostimulator and hyaluronic acid (HA) filler development by implementing Sofregen’s pioneering research on silk protein to co-develop a new generation of silk-based biostimulators that will enable immediate volume restoration and provide structure for new tissue generation.

“Galderma is a world leader in dermatology, with decades of experience in delivering cutting edge innovation in facial aesthetics and we are thrilled to have them as a partner. This agreement highlights Sofregen’s dedication to advancing the science of silk and will accelerate our ability to develop the next generation of biostimulator fillers with a recognized leader in this space,” said Jonathan T. Hartmann, CEO, Sofregen, Framingham, Massachusetts.

According to the agreement, both companies will perform specific activities related to the co-development of a portfolio of novel silk-based biostimulator fillers. Additionally, Galderma will have the exclusive option to acquire Sofregen’s Silk Voice and other assets associated with its aesthetic business. This grants Galderma all of the rights to the products co-developed by the companies, and ownership of Sofregen’s silk technology platform in the aesthetic and dermatological field.

"At Galderma, we’re committed to advancing dermatology through constant innovation and joining forces with other industry pioneers. Combining Galderma’s capabilities and scale with Sofregen’s novel silk platform represents a watershed moment for the aesthetics market through the development of a new category of biostimulator fillers designed to make an impact for healthcare professionals and their patients,” said Baldo Scassellati Sforzolini, global head of research & development, Galderma, Lausanne, Switzerland.

Galderma and Sofregen said they plan to launch development programs for all products imminently, according to the press release.


1. Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology. Galderma. Published September 23, 2021. Accessed September 24, 2021. https://www.galderma.com/news/galderma-announces-exclusive-agreement-sofregen-develop-next-generation-biostimulator-fillers

Related Videos
© 2024 MJH Life Sciences

All rights reserved.